GlassScriptPhysician profile
Nagathna Pamphil
NPI 1720795420
$5,017.32
in general payments reported to CMS, 2019-2025
19 companies · $2,446 in 2025
The $2,446 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $516 · 2024: $2,056 · 2025: $2,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,736 · Travel and Lodging: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,736.35 |
| Travel and Lodging | $280.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,608.26 | 2023-2025 | Wainua, Farxiga, Lokelma |
| Cvrx, INC. | $442.66 | 2025 | Barostim Neo System |
| Bridgebio Pharma, INC. | $428.99 | 2025 | Attruby |
| United Therapeutics Corporation | $352.50 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.57 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $268.36 | 2024-2025 | Ozempic |
| Alnylam Pharmaceuticals INC. | $263.03 | 2025 | Amvuttra, Onpattro |
| Merck Sharp & Dohme LLC | $248.30 | 2023-2025 | Verquvo |
| Scpharmaceuticals INC. | $222.08 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $211.86 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $172.64 | 2025 | Camzyos, Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $96.29 | 2024 | Arcalyst |
| Pfizer INC. | $91.55 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $64.39 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.77 | 2024 | Lifevest |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $49.09 | 2024 | Optimizer |
| Lilly USA, LLC | $41.12 | 2023-2025 | Mounjaro |
| Philips North America LLC | $38.01 | 2025 | Mcot |
| Heartflow, INC. | $22.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nagathna Pamphil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.